Thursday, September 17, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Marketsascendis pharmasemaglutidetransconglp-1

Ascendis Pharma Regains Rights to TransCon Semaglutide Program

Danish company reclaims its metabolic and cardiovascular TransCon portfolio, including a once-monthly semaglutide candidate.

TR
By Tom Reyes · Markets Editor
Sep 14 18:10 ETSource: Quiver Quantitative

The wire

  1. 01Ascendis announced it has regained rights to TransCon metabolic and cardiovascular programs.
  2. 02Portfolio includes a once-monthly TransCon semaglutide, a potential long-acting GLP-1 option.
  3. 03Development plans, partners and timelines not specified.

From the source

Ascendis Pharma Regains Rights to TransCon Metabolic and Cardiovascular Programs, Including Once-Monthly TransCon Semaglutide

Read at news.google.com
Source URL https://news.google.com/rss/articles/CBMi8gFBVV95cUxPOS1MdzFyanNaNzMwZDB1N1F1OGVPR2xjUnZYX3V5LVdNU0NQR2JtR1VoOEdkRkxjY0FRVzIxTDZWcm93VHBhZ2NHSnZhTm92dXNvWmpWTHFIMlVPY21mN0tLVFZJTmo1YTQ2dGpOU082X1U5eXhFNHUyd3BzWUNSTUZfQmVzS19tUnJPMm1DQWdINThRaUxEampoYUY3ZkEzaF9LWUgxaTNPbUdqLVVUNW93MnpKMlFzb00tZUhxRHE3cUp5LUt6dUVZQjhfWFA4QkljTUdoYURmV29oTkgxWDRlMGRXc3pjTlFqUFNqdXNtQQ?oc=5